This legislation reauthorizes and strengthens federal programs dedicated to accelerating research and expanding patient access to promising treatments for amyotrophic lateral sclerosis (ALS) through 2031.
Lisa Murkowski
Senator
AK
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends vital funding and support for ALS research and treatment access through 2031. This legislation strengthens grant application requirements, enhances FDA reporting on rare neurodegenerative disease action plans, and mandates new assessments to improve the effectiveness of ongoing programs. These updates ensure continued momentum in the development of life-saving therapies for patients living with ALS.
ALS Therapy Access Extended Through 2031: New Grant Rules and FDA Action Plans to Fast-Track Treatments
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 is essentially a lifeline extension for medical research. It pushes the expiration date of the original 2021 law from 2026 out to September 30, 2031, ensuring that federal grants and FDA programs aimed at finding a cure for ALS (Lou Gehrig’s disease) don't run out of gas. Beyond just keeping the lights on, the bill tightens the rules on how research money is spent and how drug companies report their progress to the public.
Raising the Bar for Research Grants
Section 3 of the bill makes it harder for researchers to just 'set it and forget it' once they receive federal funding. If a biotech company or a university wants a grant for an expanded access program—which allows patients who don't qualify for clinical trials to try investigational drugs—they now have to prove exactly how their data will help prevent or treat ALS (Sec. 3). They also have to give a hard 'assurance' that they won't let these programs interfere with their main clinical trials. For a family dealing with a diagnosis, this means the government is trying to ensure that 'compassionate use' of a drug doesn't accidentally slow down the official FDA approval process that would make the drug available to everyone.
Cutting Through the Red Tape
The bill also gets specific about what counts as progress. It expands the definition of 'Phase 3' clinical trials to include combined Phase 2/3 trials and even planned trials that haven't started recruiting yet (Sec. 3). This is a big deal for speed; it allows promising therapies to qualify for support earlier in the pipeline. To keep things moving, the Secretary of HHS is now required to set specific enrollment deadlines. Think of it like a 'use it or lose it' policy for research: if a trial isn't actually getting patients into seats within a certain timeframe, the funding could be at risk.
Accountability and the Five-Year Plan
Section 4 rebrands the FDA’s homework. Instead of just a one-time report, the FDA must now publish a 'Rare Neurodegenerative Disease Action Plan' every five years. These plans can’t just be vague goals; they must include a 'look back' at what they actually accomplished from the previous plan and identify specific barriers—like a lack of staff or funding—that stopped them from moving faster. For the average person, this adds a layer of transparency, forcing the bureaucracy to admit where the bottlenecks are in the drug approval process and what it will take to fix them.